|
Vaxzevria approved in the EU as third dose booster against COVID-19
|
26 May 2022 |
|
Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
|
20 April 2022 |
|
Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19
|
24 March 2022 |
|
New Vaxzevria data further support its use as third dose booster
|
13 January 2022 |
|
AstraZeneca and Ionis close agreement to develop and commercialise eplontersen
|
30 December 2021 |
|
Vaxzevria significantly boosted antibody levels against Omicron
|
23 December 2021 |
|
Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study
|
17 December 2021 |
|
Two billion doses of AstraZeneca’s COVID-19 vaccine supplied to countries across the world
|
16 November 2021 |
|
AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US
|
05 October 2021 |
|
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
|
20 August 2021 |